सिंगापुर - अंग्रेज़ी - HSA (Health Sciences Authority)

gilead sciences singapore pte. ltd. - sofosbuvir - tablet, film coated - sofosbuvir 400.0mg

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - sofosbuvir - tablet - 400mg

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - emtricitabine, quantity: 200 mg; efavirenz, quantity: 600 mg; tenofovir disoproxil maleate, quantity: 300 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium metabisulfite; hyprolose; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; ferric oxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - tenofovir disoproxil/ emtricitabine/ efavirenz mylan 300/200/600 is indicated for the treatment of hiv infected adults over the age of 18 years.,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts in controlled studies of viread, emtriva and stocrin in treatment-na?ve and treatment experienced adults.

इसराइल - अंग्रेज़ी - Ministry of Health

gilead sciences israel ltd - emtricitabine; tenofovir disoproxil as fumarate - film coated tablets - emtricitabine 200 mg; tenofovir disoproxil as fumarate 245 mg - tenofovir disoproxil - tenofovir disoproxil - truvada is indicated in combination with other anti-retroviral medicinal products for the treatment of hiv-1 infected adults over 18 years of age.truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults at high risk .

इसराइल - अंग्रेज़ी - Ministry of Health

gilead sciences israel ltd - emtricitabine; tenofovir disoproxil as fumarate - film coated tablets - emtricitabine 200 mg; tenofovir disoproxil as fumarate 245 mg - tenofovir disoproxil - tenofovir disoproxil - truvada is indicated in combination with other anti-retroviral medicinal products for the treatment of hiv-1 infected adults over 18 years of age.truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults at high risk .

इसराइल - अंग्रेज़ी - Ministry of Health

gilead sciences israel ltd - emtricitabine; tenofovir disoproxil as fumarate - film coated tablets - emtricitabine 200 mg; tenofovir disoproxil as fumarate 245 mg - tenofovir disoproxil - tenofovir disoproxil - truvada is indicated in combination with other anti-retroviral medicinal products for the treatment of hiv-1 infected adults over 18 years of age.truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults at high risk .

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

tillomed pharma gmbh - emtricitabine; tenofovir disoproxil fumarate - film-coated tablet - 200/245 milligram(s) - antivirals for treatment of hiv infections, combinations; tenofovir disoproxil and emtricitabine

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - ledipasvir; sofosbuvir - tablet - 90mg ; 400mg

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - ledipasvir 90mg;  ;  ; sofosbuvir 400mg;  ;  ;   - film coated tablet - 90mg/400mg - active: ledipasvir 90mg     sofosbuvir 400mg       excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry orange 85f13912 - harvoni is indicated for the treatment of chronic hepatitis c (chc) infection in adults and in pediatric patients 12 years of age and older or weighing at least 35 kg with genotype 1, 4, 5 or 6 without cirrhosis or with compensated cirrhosis.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - voxilaprevir, quantity: 100 mg; velpatasvir, quantity: 100 mg; sofosbuvir, quantity: 400 mg - tablet - excipient ingredients: lactose monohydrate; copovidone; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - vosevi (sofosbuvir/velpatasvir/voxilaprevir fixed-dose combination) is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adult patients, without cirrhosis or with compensated cirrhosis, who have: - genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; - genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties, clinical trials).